uniQure, a leader in human gene therapy, has been recognised by Frost & Sullivan as a 2017 Manufacturing Leadership Awards winner for outstanding achievement in Engineering and Production Technology Leadership related to its Lexington, Massachusetts gene therapy manufacturing facility.
uniQure’s Lexington-based facility is one of the largest, most versatile gene therapy manufacturing facilities in the world.
During the past 4 years, uniQure has invested more than $25 million in designing, constructing and equipping its 55,000 square foot facility with state-of-the-art laboratories and commercial-scale production capabilities. The facility offers 500 litre capacity with the ability to expand to up to 2000 L when needed.
“The innovative design of our facility, which incorporated 3D modelling and single-use components, required substantially less upfront capital expenditures and enables us to operate at significantly lower costs compared with other production systems,” stated Lance Weed, Vice President of Operations for uniQure.
“Our use of disposable components in our manufacturing process reduces the need for maintenance and testing, lowers the risk of contamination, enables rapid product changeovers, and requires substantially less personnel to operate.”
“uniQure is committed to manufacturing excellence in gene therapy and we are delighted that Frost & Sullivan has recognised our achievements in this regard,” stated Matt Kapusta, Chief Executive Officer of uniQure.
“We continue to believe that our leading manufacturing capabilities provide us a significant competitive advantage in rapidly delivering gene therapies to patients, including our lead product candidate in haemophilia B, for which we plan to begin a global pivotal study in 2018.”
uniQure will be recognised at the 13th Annual Manufacturing Leadership Awards Gala, which is to be held on the last day of the Manufacturing Leadership Summit, 12-14 June, at the Hyatt Regency Huntington Beach Resort and Spa in Huntington Beach (CA, USA).